Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 7(1): 9563, 2017 08 25.
Article in English | MEDLINE | ID: mdl-28842599

ABSTRACT

Hypoxia-induced miR-210 displays a pro-survival, cytoprotective and pro-angiogenic role in several in vitro systems. In vivo, we previously found that miR-210 inhibition increases ischemic damage. Here we describe the generation of a versatile transgenic mouse model allowing the evaluation of miR-210 therapeutic potential in ischemic cardiovascular diseases. We generated a Tet-On miR-210 transgenic mouse strain (TG-210) by targeted transgenesis in the ROSA26 locus. To functionally validate miR-210 transgenic mice, hindlimb ischemia was induced by femoral artery dissection. Blood perfusion was evaluated by power Doppler while tissue damage and inflammation were assessed by histological evaluation. We found that miR-210 levels were rapidly increased in TG-210 mice upon doxycycline administration. miR-210 overexpression was maintained over time and remained within physiological levels in multiple tissues. When hindlimb ischemia was induced, miR-210 overexpression protected from both muscular and vascular ischemic damage, decreased inflammatory cells density and allowed to maintain a better calf perfusion. In conclusion, we generated and functionally validated a miR-210 transgenic mouse model. Albeit validated in the context of a specific cardiovascular ischemic disease, miR-210 transgenic mice may also represent a useful model to assess the function of miR-210 in other physio-pathological conditions.


Subject(s)
Gene Expression , Ischemia/etiology , MicroRNAs/genetics , Animals , Biopsy , Disease Models, Animal , Fluorescent Antibody Technique , Gene Order , Gene Targeting , Genetic Vectors/genetics , Immunohistochemistry , Ischemia/metabolism , Ischemia/pathology , Mice , Mice, Transgenic
2.
Sci Rep ; 6: 24141, 2016 Apr 11.
Article in English | MEDLINE | ID: mdl-27063004

ABSTRACT

Long noncoding RNAs (lncRNAs) are non-protein coding RNAs regulating gene expression. Although for some lncRNAs a relevant role in hypoxic endothelium has been shown, the regulation and function of lncRNAs is still largely unknown in the vascular physio-pathology. Taking advantage of next-generation sequencing techniques, transcriptomic changes induced by endothelial cell exposure to hypoxia were investigated. Paired-end sequencing of polyadenylated RNA derived from human umbilical vein endothelial cells (HUVECs) exposed to 1% O2 or normoxia was performed. Bioinformatics analysis identified ≈2000 differentially expressed genes, including 122 lncRNAs. Extensive validation was performed by both microarray and qPCR. Among the validated lncRNAs, H19, MIR210HG, MEG9, MALAT1 and MIR22HG were also induced in a mouse model of hindlimb ischemia. To test the functional relevance of lncRNAs in endothelial cells, knockdown of H19 expression was performed. H19 inhibition decreased HUVEC growth, inducing their accumulation in G1 phase of the cell cycle; accordingly, p21 (CDKN1A) expression was increased. Additionally, H19 knockdown also diminished HUVEC ability to form capillary like structures when plated on matrigel. In conclusion, a high-confidence signature of lncRNAs modulated by hypoxia in HUVEC was identified and a significant impact of H19 lncRNA was shown.


Subject(s)
Cell Hypoxia , RNA, Long Noncoding/metabolism , Animals , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Disease Models, Animal , G1 Phase Cell Cycle Checkpoints , High-Throughput Nucleotide Sequencing , Human Umbilical Vein Endothelial Cells , Humans , Immunohistochemistry , Ischemia/genetics , Ischemia/metabolism , Ischemia/pathology , Male , Mice , Mice, Inbred C57BL , Oligoribonucleotides, Antisense , RNA Interference , RNA, Long Noncoding/antagonists & inhibitors , RNA, Long Noncoding/chemistry , RNA, Long Noncoding/genetics , Sequence Analysis, RNA , Transcriptome
SELECTION OF CITATIONS
SEARCH DETAIL
...